In March, the most popular stories from Interventional News included reports from the Society of Interventional Oncology (SIO) annual meeting (25–29 January 2024, Long Beach, USA); upcoming research to be presented at the Society of Interventional Radiology (SIR) annual scientific meeting (23–28 March, Salt Lake City, USA); among several more.
Sirtex Medical, a manufacturer of interventional treatment solutions, announced today the appointment of Matt Schmidt as chief executive officer and board of directors member, effective March 25, 2024.
A recent study published in the journal CardioVascular and Interventional Radiology has found conservative management may be efficacious in patients with spontaneous retroperitoneal haemorrhage (SRH), with added variable success seen after embolization in a more unstable patient group.
3. ‘A new narrative’: TACE in the age of Y90 and immunotherapy
Hotly debated across SIO annual conference programme, speakers took to the stage to contest the survival of transarterial chemoembolization (TACE) in the age of yttrium-90 (Y90) transarterial radioembolization (TARE) and immunotherapy, their compelling arguments making some audience members “more confused and others happy”.
4. EMBOLIZE pelvic venous disease study launched at SIR 2024
The Society of Interventional Radiology (SIR) Foundation, The VIVA Foundation and Penumbra, today announced the launch of the EMBOLIZE trial, a first-of-its-kind prospective, randomised controlled trial studying the effects of ovarian vein embolization (OVE) and pelvic vein embolization in reducing pain in women experiencing chronic pelvic pain due to pelvic venous disease (PeVD).
5. BD announces first patient enrolled in PAD vascular covered stent trial
BD has announced the enrolment of the first patient in the AGILITY investigational device exemption (IDE) study, which will assess the safety and effectiveness of the BD vascular covered stent for the treatment of peripheral arterial disease (PAD).
Set to be presented at the upcoming Society of Interventional Radiology (SIR) annual scientific meeting, an anticipated late-breaking analysis of the BEST-CLI (Best endovascular versus best surgical therapy in patients with critical limb ischaemia) trial will expose the cause and significant impact that endovascular technical failure (ETF) had on patient outcomes.
New research to be presented at the Society of Interventional Radiology (SIR) annual scientific meeting has found early intervention with uterine artery embolization (UAE) can help women avoid hysterectomy due to severe bleeding after childbirth.
8. Cryoablation highly effective for breast cancer patients with large tumours
Cryoablation—minimally-invasive technique that uses ice to freeze and destroy small, cancerous tumours—has now been proven effective for breast cancer patients with large tumours, providing a new treatment path for those who are not candidates for surgery, according to new research to be presented at the Society of Interventional Radiology (SIR) annual scientific meeting.
9. Society of Interventional Oncology announces third European site approved in ACCLAIM trial
The Society of Interventional Oncology (SIO) announces the European Institute of Oncology (IEO) in Milan, Italy, as the next European site approved for enrolment and activated for the society’s primary clinical trial, Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) prospective trial for microwave ablation as a local cure.
10. Getinge and Cook Medical enter US commercial distribution agreement for iCast covered stent
Getinge and Cook Medical today announced an exclusive sales and distribution agreement for the iCast covered stent system, which recently received US Food and Drug Administration premarket approval for the treatment of symptomatic iliac arterial occlusive disease.
